Blarcamesine is a sigma 1 receptor agonist which targets Alzheimer's pathology upstream of amyloid and tau pathology.

SAN DIEGO -- Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 ...

High levels of “hidden” fat known as visceral fat may put you at higher risk for Alzheimer’s disease up to two decades before ...

First author Hamilton Oh, now at Icahn School of Medicine at Mt. Sinai, New York, and colleagues identified these potential markers during a proteomics analysis of CSF from 3,397 participants in six ...

Roche's trontinemab data showed dose-dependent amyloid reduction in Alzheimer's patients, while its Elecsys pTau181 test aims ...

The assays measure phosphorylated tau 181 and apolipoprotein 4 to rule out whether a patient has Alzheimer's disease.

Genentech announced that new data were presented at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s ...

Researchers have developed a blood test based on a protein biomarker for tau tangles that can help diagnose Alzheimer’s ...

Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

Roche Holding said it will initiate a late-stage trial for its Alzheimer's drug candidate trontinemab later this year after its mid-stage study showed positive results.

Trontinemab is currently being studied in the Phase Ib/IIa Brainshuttle AD study assessing the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of trontinemab in participants with ...

A new study finds that even light-to-moderate alcohol consumption may be linked to increased amyloid beta deposition, a key ...